research use only
Cat.No.S1397
|
In vitro |
DMSO
: 122 mg/mL
(200.1 mM)
Water : 122 mg/mL Ethanol : 122 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 609.68 | Formula | C32H53N2O4.Br |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 119302-91-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | ORG 9426 | Smiles | CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-] | ||
| Targets/IC50/Ki |
AChR
|
|---|---|
| In vitro |
Rocuronium bromide (RB), an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively.
|
| In vivo |
Rocuronium is an ideal muscle relaxant with a rapid onset, intermediate duration of action, nondepolarizing properties and lack of cardiovascular side effects. Rocuronium produces a dose-dependent duration of neuromuscular blockade in isoflurane anesthetized horses. Rocuronium bromide, is a relatively low potency, intermediate-acting agent with a rapid onset time of 98 seconds in dogs. Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. Rocuronium has a rapid onset, a short duration of action. Rocuronium (0.6 mg/kg) results in a significant increase in heart rate one min after IV administration in the dog. Rocuronium (0.3 mg/kg and 0.6 mg/kg) produce a reliable neuromuscular block of 23–32 min duration, respectively. Rocuronium bromide paralyzes the internal laryngeal muscles keeping the vocal cords in an intermediate position (paramedial) 60 seconds after being administered in cats.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05619848 | Completed | Spinal Stenosis Lumbar |
Zheng Guo|Second Hospital of Shanxi Medical University |
October 25 2022 | Early Phase 1 |
| NCT00675792 | Completed | Anesthesia |
Merck Sharp & Dohme LLC |
May 2008 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.